AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🌍 Showing

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Condition

Country

City (shown first)

30 recruiting trials

for Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) NCT03936153Phase 223 sites📍 Beijing📍 Beijing📍 Beijing Xynomic Pharmaceuticals, Inc. · Tests: abexinostat SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265Phase 15 sites📍 Denver📍 Atlanta📍 Fairway Verismo Therapeutics · Tests: SynKIR-310 Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL NCT05552937Phase 21 site📍 Hangzhou Beijing InnoCare Pharma Tech Co., Ltd. · Tests: Tafasitamab and Lenalidomide Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) NCT06299553n/a1 site📍 Milan Incyte Biosciences Italy S.r.l A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies NCT07735533Phase 1, Phase 21 site📍 Nashville Umoja Biopharma · Tests: UB-VV400, Rapamycin (sirolimus) A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558Phase 336 sites📍 Gilbert📍 Scottsdale📍 Scottsdale Lyell Immunopharma, Inc. · Tests: rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma NCT07189065Phase 241 sites📍 Hefei📍 Beijing📍 Beijing Guangzhou Lupeng Pharmaceutical Company LTD. · Tests: Rocbrutinib, Bendamustine, Rituximab, Lenalidomide Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma NCT06649812Phase 2114 sites📍 Tucson📍 Tucson📍 Los Angeles National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma NCT07570017Phase 12 sites📍 Guangzhou📍 Shanghai Guangzhou Lupeng Pharmaceutical Company LTD. · Tests: Rocbrutinib, R-GemOx A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) NCT05139017Phase 2, Phase 3135 sites📍 Glendale📍 Beverly Hills📍 Walnut Creek Merck Sharp & Dohme LLC · Tests: Zilovertamab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Bendamustine Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma NCT05272384Phase 19 sites📍 Birmingham📍 Duarte📍 Sacramento National Cancer Institute (NCI) · Tests: Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Nivolumab, Positron Emission Tomography Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma NCT07062627Phase 21 site📍 Seoul Hyungwoo Cho · Tests: Anbal-cel Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma NCT06830031Phase 11 site📍 Tianjin Shanghai Exuma Biotechnology Ltd. · Tests: C402-CD19-CAR Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma NCT07725406Phase 11 site📍 New York Weill Medical College of Cornell University · Tests: Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherap… A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma NCT07570823Phase 31 site📍 Beijing Sinocelltech Ltd. · Tests: SCTB35 injection, Rituxumab, Gemcitabine, Oxaliplatin Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma NCT07249905Phase 1, Phase 22 sites📍 Richmond📍 Nedlands ModeX Therapeutics, An OPKO Health Company · Tests: MDX2003 Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL NCT04502394Phase 1, Phase 245 sites📍 Goshen📍 Cincinnati📍 Columbus Kartos Therapeutics, Inc. · Tests: KRT-232, acalabrutinib Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure NCT06918912Phase 27 sites📍 Alessandria📍 Bologna📍 Cuneo Istituto Clinico Humanitas · Tests: Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate) Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination. NCT07489989Phase 21 site📍 Beijing Daihong Liu · Tests: CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance DALY II Japan/MB-CART2019.1 for DLBCL NCT07288879Phase 25 sites📍 Tokyo📍 Tokyo📍 Tokyo Miltenyi Biomedicine GmbH · Tests: MB-CART2019.1 Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma NCT04512716EARLY Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: 131-I Apamistamab, CAR T-cell Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients NCT04836507Phase 1, Phase 22 sites📍 Seoul📍 Seoul Curocell Inc. · Tests: CRC01, Fludarabine, Cyclophosphamide Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL NCT06682130Phase 21 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: Group A：Patients with PR or ctDNA positivity after salvage treatment, Group B: Patients with CR and ctDNA negative afte… IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL NCT06768905Phase 1, Phase 21 site📍 Dallas University of Texas Southwestern Medical Center · Tests: Iomab-B, CAR-T cell Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL NCT07255963Phase 21 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: Pirtobrutinib, Lisaftoclax, Rituximab A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL NCT06375733Phase 1, Phase 22 sites📍 Nanning📍 Zhengzhou Genfleet Therapeutics (Shanghai) Inc. · Tests: GFH009, Zanubrutinib, GFH009, Zanubrutinib Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies NCT06980116Phase 117 sites📍 Tbilisi📍 Athens📍 Pátrai Exscientia AI Ltd., a wholly owned subsidiary of Recursion … · Tests: EXS73565 Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse NCT03356054Phase 1, Phase 21 site📍 Rotterdam Stichting Hemato-Oncologie voor Volwassenen Nederland · Tests: R-DHAP, Brentuximab Vedotin Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma NCT06047197Phase 11 site📍 Tianjin Beijing Yongtai Ruike Biotechnology Company Ltd · Tests: RC19D2 cell injection A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL) NCT06789159Phase 11 site📍 Lexington Pierluigi Porcu · Tests: VK-2019

🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy